Psychedelic research and therapy going underground

Psychedelic research and therapy going underground was not simply the disappearance of psychedelic treatment after its public and institutional suppression. It was a change in where the work happened, who carried it forward, and how it was organized: from sanctioned research programs to a dispersed network of guides who continued using psychedelics in carefully structured therapeutic and spiritual practice. That transition preserved knowledge through decades when universities largely stopped studying the drugs, and left a legacy that later returned to clinical research while reopening questions about medicine’s authority over psychedelic experience.

From university research to the underground

By the end of 1962, Timothy Leary and Richard Alpert had concluded that psychedelic research had become too controversial for a university setting. After Harvard imposed new restrictions, they announced the International Federation for Internal Freedom as a new home for their work and objected to expanded federal authority over experimental drugs. They framed the restrictions as a civil-liberties question about who could explore and regulate consciousness. Their move did more than transfer a research project to another institution: it declared a break with the effort to keep psychedelics within conventional academic science. Leary described the change to David McClelland as an end to playing the science game, and the pair now pursued cultural transformation instead.

This departure took place amid a deeper conflict over what psychedelic treatment was. Earlier models had been easier for psychiatry to accommodate: the psychotomimetic model treated drug effects as resembling mental illness, while the psycholytic model made the drugs adjuncts to psychoanalysis. Psychedelic therapy proposed a different arrangement, often organized around a single high-dose session intended to produce a profound change in perspective. It challenged customary roles for therapist and patient, and carried spiritual elements into clinical practice. Charles Grob later characterized this boundary-crossing approach as applied mysticism. Its reliance on set and setting also made the therapist’s conduct and the surrounding environment part of the treatment, complicating the idea that a drug’s effects could be isolated and tested independently.

The same features that made the approach therapeutically promising made it difficult to defend within psychiatry’s changing standards. In the aftermath of the thalidomide tragedy, the federal government strengthened regulation of experimental drugs, while the double-blind, placebo-controlled trial gained authority as the preferred standard for evaluating them. Psychedelics posed particular problems for that design: participants and guides could often tell whether psilocybin or a placebo had been administered, and the influence of expectation, setting, and therapeutic relationship could not readily be separated from the drug. Professional critics also objected to researchers’ spiritual interests and personal experience with psychedelics. The result was not one simple institutional decision, but a growing mismatch between the field’s methods and the categories through which academic medicine judged legitimate research.

A dispersed profession and its lineages

The underground that followed was not synonymous with illegal drug manufacture, sale, or casual use. Michael Pollan describes a smaller world of perhaps a few hundred guides and therapists who worked with psychedelic substances according to prescribed practices, aiming to treat illness or support spiritual, creative, and emotional development. Some held professional credentials and risked their licenses as well as their freedom; others came from religious professions, described themselves as shamans, or combined therapeutic training from several alternative traditions. Pollan reports interviewing fifteen guides and working with five. Their range of backgrounds was wide, but their work often drew on practices inherited from the earlier generation of psychedelic research.

Many practitioners traced a professional lineage to Timothy Leary, Stanislav Grof, Al Hubbard, or the Bay Area psychologist Leo Zeff, often through a former student or colleague. Zeff became one of the best-known underground therapists after deciding to continue his work when federal restrictions made psychedelic use illegal for any purpose. He found that psychedelic sessions could help patients move beyond defenses and encounter unconscious material and spiritual insights. His decision to persist carried a personal cost, but he justified it by the results he believed he saw in patients. The underground therefore transmitted more than access to substances: it maintained a body of therapeutic experience through teachers, training, and the practical inheritance of methods.

Zeff also helped make that inheritance more explicit. He developed agreements that set expectations around strict confidentiality, the prohibition of sexual contact, and the participant’s compliance with guidance during a session. He considered it important for guides to have personal experience with the medicines they administered. At the same time, he urged them not to steer a client’s journey toward a predetermined destination. Rather than maintain the analyst’s detached mask in every circumstance, a guide could offer emotional presence and comforting physical reassurance when a client was struggling. These practices marked a departure from some conventional therapeutic norms, but they were intended to place responsibility for the participant’s safety and experience within a clear relationship.

Protocols as a cultural container

By the time the underground guides began to gather and share documents, their work had acquired features of a profession without becoming a formal organization. At a psychedelic-science conference in San Jose, James Fadiman invited guides to meet the following morning, expecting only a handful; about a hundred attended. Their numbers did not prove that they constituted a unified community, but the meeting revealed a substantial and previously little-seen network. A collaborative online site soon offered draft documents, including a charter focused on making profound experiences more available and practical resources for people preparing to guide or undertake them.

The materials addressed the vulnerabilities created by psychedelic suggestibility. A Code of Ethics for Spiritual Guides emphasized disclosure of risks, consent, confidentiality, health and safety, restraint in self-promotion, and service without regard to a client’s ability to pay. Legal-release forms, ethical agreements, and medical questionnaires offered further structure. Guidelines for Voyagers and Guides gathered advice on preparation, drug interactions, intention, the stages of a session, frightening experiences, and post-session integration. Together, these documents made visible an accumulated practice: a set of rules and rituals meant to channel an experience that could not be reduced to pharmacology alone.

This effort to create a cultural container echoed an earlier contribution associated with Al Hubbard and other first-wave therapists. The models of psychedelic use had each tried to regulate powerful drugs through protocols and an account of what the experience was for. In the underground, those questions became practical matters of preparation, conduct, and responsibility. The analogy is not that clinical medicine and underground practice were interchangeable. Rather, they represented different ways of containing an experience that could be dangerous when left without reliable guidance or shared expectations. The guides’ accumulated standards also offered a counterweight to the do-it-yourself use that had accompanied the drugs’ movement beyond the laboratory.

Knowledge returns to research

The underground’s separation from academic institutions was never complete. According to Myron Stolaroff, research that resumed in the late 1990s drew partly on the anecdotal evidence accumulated by underground therapists as well as on studies from the 1950s and 1960s. Some guides were later recruited to help train practitioners for university trials. When the Johns Hopkins team wanted to investigate music in guided psilocybin sessions, it sought information from underground guides about their musical practices. This exchange gave the underground a role in research even when university investigators were cautious about acknowledging that connection.

The clinical revival also renewed the methodological problem that had helped marginalize psychedelic therapy. Researchers could not easily blind participants to the effects of psilocybin, nor cleanly separate the substance from a guide’s presence, the session’s setting, or a volunteer’s expectations. If treatment worked partly by furnishing an experience that changed how a person understood their life, it challenged a model of psychiatric medication focused on isolating a chemical effect. Grob’s defense of applied mysticism expressed the tension plainly: scientific rigor remained necessary, but researchers might also need to attend to the therapeutic features of the setting and the shamanic traditions that had long organized powerful experiences.

Results from the New York University and Johns Hopkins cancer studies helped make psychedelic therapy more respectable again. In trials totaling eighty subjects, about 80 percent of participants showed clinically significant reductions in anxiety and depression, with effects lasting at least six months; the intensity of reported mystical experience closely tracked symptom improvement. The studies were small and required larger replication before regulatory change could be considered, but they attracted support from mental-health leaders, medical schools, and funders. At New York University, the treatment room moved from the dental college toward the main hospital, and the cancer center asked for a room for a future trial. These institutional changes showed how knowledge preserved beyond conventional research could return to it, though under new scrutiny and standards.

Medical acceptance and its limits

The revival did not settle the question of what psychedelic therapy should become. At a later conference, former leaders of the mental-health establishment welcomed the promise of psychedelic-assisted psychotherapy while warning that safety, rigor, and reputational risks could not be neglected. Bob Jesse, by contrast, worried that making medicalization the sole route to acceptance would narrow the possibilities. Others, including Rick Doblin and Katherine MacLean, imagined forms of cultural acceptance extending beyond treatment of illness, though they differed over legalization and control. Jesse favored trained guides working within continuing, multigenerational contexts; another proposal envisioned a supervised mental-health club for people seeking an experience for health, spiritual, or exploratory reasons.

The underground’s significance lies in this unresolved inheritance. Its practitioners kept therapeutic knowledge alive when approved research had largely stopped, created professional safeguards without the full protection of institutional legitimacy, and passed practices back into university settings. Yet the return to medicine did not erase the earlier argument over who should guide psychedelic experience or what ends it should serve. Medical trials offered one possible structure; the underground had developed another. The history of the transition is therefore not a simple passage from illegality to acceptance, but an ongoing negotiation between clinical treatment, spiritual practice, and broader claims about human development.